Skip to main content

A new weapon in the fight against metastasis

Media mentions
5 Nov 18




Communication Officer
Tel.+34 93 40 37255

The “Dinero” supplement of the newspaper La Vanguardia has interviewed Roger Gomis, ICREA researcher at IRB Barcelona, about Inbiomotion, a spin-off from the institute and ICREA. This company, which came about from biomedical research and an entrepreneurial spirit, develops and commercialises a diagnostic test that allows the identification of those breast cancer patients most likely to develop bone metastasis. “It is very satisfying that an idea that arose in a lab has found a favourable environment in Barcelona in which to take a potentially life-saving product onto the market,” says Gomis.

Link to La Vanguardia


About IRB Barcelona

Created in 2005 by the Generalitat de Catalunya (Government of Catalonia) and University of Barcelona, IRB Barcelona is a Severo Ochoa Centre of Excellence, a seal that was awarded in 2011. The institute is devoted to conducting research of excellence in biomedicine and to transferring results to clinical practice, thus improving people’s quality of life, while simultaneously promoting the training of outstanding researchers, technology transfer, and public communication of science. Its 28 laboratories and eight core facilities address basic questions in biology and are orientated to diseases such as cancer, metastasis, Alzheimer’s, diabetes, and rare conditions. IRB Barcelona is an international centre that hosts 400 employees and more than 30 nationalities. It is located in the Barcelona Science Park. IRB Barcelona is a CERCA center, and a member of the Barcelona Institute of Science and Technology (BIST).